Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Mefloquine
Drug ID BADD_D01369
Description Malaria is a protozoan disease that places an enormous burden on human health in endemic areas around the world. The 2020 World Health Organization malaria report indicates a 60% decrease in the global malaria fatality rate between 2000 to 2019.[L30618] Despite this, malaria remains a significant cause of morbidity and mortality; 90% of deaths from malaria occur in Africa. Individuals at the highest risk for malaria are those in disease naïve populations, children under age 5, refugees in Central and Eastern Africa, nonimmune civilian and military travelers, pregnant women, and immigrants traveling to their place of origin.[L30623] Mefloquine, commonly known as Lariam, is an antimalarial drug used for the prevention and treatment of malaria caused by infection with Plasmodium vivax and Plasmodium falciparum. The drug was initially discovered by the Walter Reed Army Institute of Research (WRAIR) during a malaria drug discovery program between 1963 until 1976. It was approved by the FDA in 1989, and was first marketed by Hoffman Laroche.[A226838] This drug has been the subject of widespread controversy due to concerns regarding neurotoxic effects; product information warns of potential serious neuropsychiatric effects.[A226838,L8953]
Indications and Usage For the treatment of mild to moderate acute malaria caused by Mefloquineuine-susceptible strains of Plasmodium falciparum (both chloroquine-susceptible and resistant strains) or by Plasmodium vivax. Also for the prophylaxis of Plasmodium falciparum and Plasmodium vivax malaria infections, including prophylaxis of chloroquine-resistant strains of Plasmodium falciparum.
Marketing Status Prescription; Discontinued
ATC Code P01BC02
DrugBank ID DB00358
KEGG ID D04895
MeSH ID D015767
PubChem ID 4046
TTD Drug ID D0GQ7K
NDC Product Code Not Available
Synonyms Mefloquine | Mephloquine | WR-177,602 | WR 177,602 | WR177,602 | Ro-21-5998-001 | Ro 21 5998 001 | Ro215998001 | WR-142,490 | WR 142,490 | WR142,490 | Lariam | Mefloquine Hydrochloride
Chemical Information
Molecular Formula C17H16F6N2O
CAS Registry Number 49752-90-1
SMILES C1CCNC(C1)C(C2=CC(=NC3=C2C=CC=C3C(F)(F)F)C(F)(F)F)O
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Dermatitis bullous23.03.01.002--
Diarrhoea07.02.01.001--
Discomfort08.01.08.003--Not Available
Dizziness24.06.02.007; 17.02.05.003; 02.01.02.004--
Drug interaction08.06.03.001--Not Available
Dyspepsia07.01.02.001--
Dysphagia07.01.06.003--
Dyspnoea22.02.01.004; 02.01.03.002--
Ear disorder04.03.01.001--Not Available
Emotional disorder19.04.02.005--Not Available
Encephalopathy17.13.02.001--
Epilepsy17.12.03.002--Not Available
Erythema23.03.06.001--Not Available
Erythema multiforme23.03.01.003; 10.01.03.015--
Extrasystoles02.03.02.003--Not Available
Eye disorder06.08.03.001--Not Available
Fatigue08.01.01.002--
Feeling abnormal08.01.09.014--Not Available
Flushing23.06.05.003; 08.01.03.025; 24.03.01.002--
Gastrointestinal disorder07.11.01.001--Not Available
Gastrointestinal pain07.01.05.005--
Glucose-6-phosphate dehydrogenase deficiency14.14.03.001; 03.08.03.001; 01.06.05.001--Not Available
Haematocrit decreased13.01.05.001--Not Available
Haemolysis01.06.04.002--
Hallucination19.10.02.002--
Headache17.14.01.001--
Heart rate abnormal13.14.04.006--Not Available
Heart rate irregular13.14.04.003--Not Available
Hepatic failure09.01.03.002--
Hepatocellular injury09.01.07.008--Not Available
The 2th Page    First    Pre   2 3 4 5    Next   Last    Total 5 Pages